PT - JOURNAL ARTICLE AU - Santi Nolasco AU - Raffaele Campisi AU - Claudia Crimi AU - Nicola Scichilone AU - Morena Porto AU - Gabriella Guarnieri AU - Alberto Papi AU - Bianca Beghé AU - Pietro Impellizzeri AU - Nunzio Crimi TI - Real-World Experience with dupilumab in Severe Asthma: One year data from an Italian Named Patient Program AID - 10.1183/13993003.congress-2021.PA3743 DP - 2021 Sep 05 TA - European Respiratory Journal PG - PA3743 VI - 58 IP - suppl 65 4099 - http://erj.ersjournals.com/content/58/suppl_65/PA3743.short 4100 - http://erj.ersjournals.com/content/58/suppl_65/PA3743.full SO - Eur Respir J2021 Sep 05; 58 AB - Background: Dupilumab is a monoclonal antibody targeting IL-4Rα recently licensed for Severe Asthma (SA). A Named Patients Program (NPP) was created in Italy before the its commercial availability for SA patients with no other available therapeutic options.Aim: To assess the real-world effectiveness of dupilumab in patients with SA.Methods: We performed a multicentre retrospective study, including SA patients admitted in the NPP treated with dupilumab for 12 months. Exacerbations, Asthma Control Test (ACT), pre-bronchodilator FEV1%, oral corticosteroid (OCS) intake, FeNO and eosinophils count in peripheral blood were recorded at baseline and after 3 and 12 months.Results: We included 18 SA patients (mean age 53.3±12.4 years, 66.7% female). Eleven (11/18, 61.1%) were OCS dependent. Five patients (5/18, 27.8%) received previous anti-IgE and/or anti-IL5 treatment. Significant improvements in ACT score (15.7±5.1 to 18.8±4.8, p=0.023), OCS intake [10 (5-25) mg/day to 0 (0-5) mg/day, p=0.0333] and FeNO [25 (20-80) ppb to 21 (10.9-55.3) ppb, p=0.0190] already after 3 months of treatment. After 12 months A statistically significant decrease in the number of exacerbations from 2 (0-3) to 0 (0-1) (p<0.0068) and increase in FEV1% from 73.5±19.5% to 87.1±19.2% (p=0.0407) and ACT to an average of 22.4±1.7 (p<0.0001) and the interruption of OCS in every patients (p<0.0001) was observed at 12 months. A transient increase in eosinophils was observed in five patients, with 2 surpassing 1000 cells/μL after 3 months, without any clinical effects.Conclusion: Dupilumab improved all the explored clinical outcomes after 12 months. Transient hypereosinophilia did not modify treatment response.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3743.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).